NSE: EMAMILTD | BSE: 531162

Mid-range Performer

Download real time

566.90 6.25 (1.11%)

34.08% Fall from 52W High

122.4K NSE+BSE Volume

NSE 30 Jul, 2025 2:20 PM (IST)

24,745.2

Market Cap

Above industry Median

0.7

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Emami Ltd. is on 31 Jul 2025 for the purpose of Quarterly Results See details

Emami Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for EMAMILTD, BSE:531162 Emami Ltd.

Emami Ltd.

26 Oct 2017

566.90

1.11%

Emami: EBITDA above estimate; recovery seen in wholesale channel

Buy: Emami Ltd.

Motilal Oswal

2QFY18 sales grew 9.7% YoY to INR6.3b. Domestic revenue rose 14% YoY, with 10% volume growth. The quarter continued to see CSD and wholesale channel destocking, but there has been significant recovery compared to 1QFY18. HMN...

Number of FII/FPI investors increased from 337 to 349 in Jun 2025 qtr.

Emami Ltd.

26 Oct 2017

566.90

1.11%

Emami

Buy: Emami Ltd.

Sharekhan

Boroplus Cream and 7-in-one oils continue to perform well; Navratna saw recovery in sales: Boroplus range grew by 38%, driven by strong double-digit growth in Boroplus antiseptic cream. Navratna range grew by 16%, led by double-digit volume growth in cooling oil and cool talc. 7-in-one oil continued to gain good traction and registered double-digit volume...

Emami Ltd. has lost -29.00% in the last 1 Year

Emami Ltd.

08 Aug 2017

566.90

1.11%

Result Update - Emami

Sell: Emami Ltd.

Axis Direct

Q1FY18 below expectations: Consolidated net sales declined 16%, while EBITDA and adj PAT plummeted 46% and 56% YoY. India sales declined 16% with volume decline at ~20% YoY. International sales fell 19% due to sustained pressure in MENAP business (-42% YoY).

Emami Ltd. is trading below all available SMAs

Emami Ltd.

03 Aug 2017

566.90

1.11%

Emami (1QFY18): Optimisum continues. Maintain BUY

Buy: Emami Ltd.

HDFC Securities

We expect EPS CAGR of 19% over FY17-20. We value Emami based on P/E of 35x on Jun-19 EPS. Our TP is Rs 1,301. We maintain our BUY rating. Emamis net revenues contracted by a sharp 16% to Rs 5.4bn (vs. expectations of -8%). Domestic business (85% of total) declined by 16%, with an 18% volume decline. International was under pressure, and contracted by 19%. EBITDA/APAT up by -46/-55%. Domestic biz was impacted by channel destocking. Management is confident of a strong growth recovery in 9MFY18 (July recovery was inspiring). We remain optimistic for Emamis domestic business, and expect 14% revenue CAGR over FY17-20.

Emami Ltd. has lost -29.00% in the last 1 Year

Emami Ltd.

23 May 2017

566.90

1.11%

Emami Ltd Q4FY17 results comment

Results Update: Emami Ltd.

HDFC Securities

Revenue decreased by 20.35% to Rs. 577.58 Cr in Q4FY17 when compared to the previous quarter.

Emami Ltd. has an average target of 813.14 from 7 brokers.

Emami Ltd.

09 May 2017

566.90

1.11%

Emami (Resuming Coverage): Better days ahead. BUY

Buy: Emami Ltd.

HDFC Securities

Emami is one of the leading and fastest-growing personal and healthcare companies in India. It boasts of an enviable portfolio of household brands such as Boroplus, Navratna, Fair and Handsome, Zandu and Mentho Plus Balm, Kesh King, Sona Chandi and Zandu Chyawanprash and Fast Relief.

Emami Ltd. has an average target of 813.14 from 7 brokers.

Is Emami Ltd. worth buying?

223 Votes:

Buy 74.44%

Sell 17.49%

Hold 8.07%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf